+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ALIVUS

Alivus Life Sciences Share Price

₹1,386.70 +12.1 (0.88%)
New 52W High in past week

14 Aug, 2026 3:51 PM (IST)

Alivus Life Sciences live price: ₹1,386.70. It opened at ₹1,375 vs previous close ₹1,375; intraday high/low: ₹1,395/₹1,362. The 50 & 200 DMA stand at ₹1,184.00/₹1,055.60.

Alivus Life Sciences Performance

  • Today's Low
  • ₹1,362
  • Today's High
  • ₹1,395
  • 52 Week Low
  • ₹819
  • 52 Week High
  • ₹1,418
  • Open Price₹1,375
  • Previous Close₹1,375
  • Volume87,313
  • 50 DMA₹1,184.00
  • 100 DMA₹1,115.60
  • 200 DMA₹1,055.60

Alivus Life Sciences Chart

Investment Returns

  • Over 1 Month + 19.42%
  • Over 3 Month + 30.32%
  • Over 6 Month + 50.76%
  • Over 1 Year + 46.88%

Smart Investing Starts Here Start SIP with Alivus Life Sciences for Steady Growth!

Invest Now

Alivus Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 28.2
  • PEG Ratio
  • 1.3
  • Market Cap Cr
  • 17,025
  • P/B Ratio
  • 5.1
  • Average True Range
  • 46.6
  • EPS
  • 49.1
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 69.9
  • RSI
  • 73.49
  • MFI
  • 91.75

Latest Stock News Updates

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Please find enclosed herewith Newspaper Advertisement of Notice of 15th Annual General Meeting and E-Voting information.

Alivus Life Sciences Ltd - 543322 - Business Responsibility and Sustainability Reporting (BRSR)

Please find enclosed herewith the Business Responsibility & Sustainability Report for FY 2025-26

Alivus Life Sciences Financials

Alivus Life Sciences Technicals

EMA & SMA

Current Price
₹1,386.70
+ 12.1 (0.88%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,269.80
  • 50 Day
  • ₹1,184.00
  • 100 Day
  • ₹1,115.60
  • 200 Day
  • ₹1,055.60

Resistance and Support

1381.03 Pivot Speed
  • R3 1,434.00
  • R2 1,414.40
  • R1 1,400.60
  • S1 1,367.20
  • S2 1,347.60
  • S3 1,333.80

Alivus Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-30 Quarterly Results
2026-05-14 Audited Results & Final Dividend
2026-01-22 Quarterly Results
2025-11-06 Quarterly Results
2025-08-01 Quarterly Results
Date Purpose Remarks
2025-09-01 FINAL Rs.5.00 per share(250%)Final Dividend
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend
View Alivus Life Sciences Dividend History Arrow

Alivus Life Sciences Shareholding Pattern

74.87%
12.42%
5.65%
5.54%
1.53%

About Alivus Life Sciences

Alivus Life Sciences is engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients. View More
  • NSE Symbol
  • ALIVUS
  • BSE Symbol
  • 543322
  • Executive Director,Managing Director,Chief Executive Officer
  • Yasir Yusufali Rawjee
  • ISIN
  • INE03Q201024

Similar Stocks to Alivus Life Sciences

Alivus Life Sciences FAQs

Alivus Life Sciences share price is ₹1,386 As on 15 August, 2026 | 14:52

The Market Cap of Alivus Life Sciences is ₹17024.7 Cr As on 15 August, 2026 | 14:52

The P/E ratio of Alivus Life Sciences is 28.2 As on 15 August, 2026 | 14:52

The PB ratio of Alivus Life Sciences is 5.1 As on 15 August, 2026 | 14:52

The 52 week High & Low of Alivus Life Sciences is ₹1418/₹819 respectively As on 15 August, 2026 | 14:52

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23